Allergan in-licenses Merck’s CGRP migraine development program

7 July 2015

Ireland-incorporated Allergan (NYSE: AGN) has entered into an agreement to acquire exclusive worldwide rights to US pharma giant Merck & Co's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists.

These are being developed for the treatment and prevention of migraine, and the deal is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).

Just a day earlier, acquisitive Allergan (the new name for Actavis since its recent takeover of Allergan) announced plans to buy ophthalmic devices firm Oculeve for $125 million (The Pharma Letter July 6) and last month’s $2.1 billion bid for KYTHERA Biotherapeutics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK